============================: THU.FEB,980212 :============================16:15| NYSBC:(NASD:SGPH)9802 . Harry`s@HanoverSq .SIGA Pharm . mucosal vaccine|16:45| David deWeese Chmn & DenisHruby ( Teky )  | Pure play in infectious desease . Novel antibiotics . Some yrs ago SurgeonGen declared victory | Resurgent Deseases : TB , HIV . Organ Xplant . Cancer Contagious ? | New links to microbes : Ulcers , Mucosal Vacines & Novel molecular targets - surface proteins . Body has internal & surface immune systems . aiming @ Strep Throat ,  Periodontal . Gram Positive Vectors protiase inhibitor surface haris : STD : HIV HSV HPV |  chaperones & ushers New Antibotics : Protease Inhib . Partners : Strep - NIH   | Periodontal : - SUNY Buffalo . BobJenko| Herpes - Chiron | Gram-Positive Prodease Inhib - WyethAyerst of AmerHomeProducts ( $25M ) - enzyme & screen . GramNeg Chaperon/Usher Inhib - Medimmune|16:55| DennisRuby : bacteria tries to stik to tissue - make antibodys bind to fuzz . or shave | Mucosal Surfaces : .9 of all infections . Immune mechanisms present . They take symbiotic bactieria : Fus Gene for vacine to Gram+ Commensal Bacteria . | antiHistomines ? chem - just response . Topical vacines - spray or lotion . no refrigeration . Grp a Streptococcal : Strp - FlesthEating Nderotizing fascitis VinceMachetti - Surfase protein Struct : thru cell wall . Teeth bacteria Phase 1 funded by NIH . | Periodotal Dease Mkt 67M . 6B$ % yr Porphyromonas is principal adult pathogen . they keep from sticking . Georgetown U : Paploma warts Mkt Potential : US $7B | WW $22B | Escalating Resistance - several B$ mkts . Siga going after new target - surface protein fuzz . break link between protein thru cell wall & interior membrain generator . Gram- ( e.coli Salmonella pili targets - block usher or chaperon in  periplasm SurfaceProteinXpression . Just receive notice of allowance of general patent|17:9| Davit : 13 Separat Families of Patents  Med Tek Board : Vince Fischettic , Robert Genco .. Richard Krause Commercialization : Partner vectors & Vaccines p  Funding : Rockefiller OrigonSt NIH . Comperables :  NVX  NEDI  AVIR CNTB MCDE  MMP CBST SGPH .                850  850   366  184  116   93  73   31   | M$ mkt caps|17:14| ?s | Prods in Phase 3 ? 0 . Co into 3rd yr next Nov . IPO last Sep | expect Phase 3 - product approval - 4yrs out . | Wheth ? paying res costs . 25M$ + 2 milestone paymens already . 1.5M$  this yr . Get royalties when Patent status - inhuman testing ? already done in animals . Periodotal dental creme ? like fluoride hygenist application . Mucosal ? lyden rather than receptor . put in living bugs continue to reproduce . Live like smallpox or polio . | cash flow from drug cos ? right . looking for more ; Comfortable ? as long  as covered 3x yr cash requirment . | FDA time ? starting human - 1 safety , 2 dosing , 3 safty& effacacy . | Generality of patents ? ID Biomed Vancouver working on strep vacine - have  doubts cause like go after infulenza . Rockefeller : adults rarely get  strep because evenutally recognize fuzz | Flu mkt ? lot of competion - late to pty . would luv to find way to blok . | Hospitals are dangerous - anything living there is resistant . lots of  bugs can`t make vacines against . Can give vaccine after strep infection .  - like jump starting adult response mechanism . Strep  2 - 12 yr olds get . | FDA - woman w flesh eating grp A strep . FDA has vendetta against this bug | talking to places - tropics - where bugs endemic . | TedF : overseas before US approval ? Is need . aiming at children . live . | Secondary ? if see stock @ 7-8 , hopefully scnd half 98 . | antibiotics - take substance from one microbe to kill another . war 100s  of M yrs in progress . | 9 months thru Phase 2 | MikeStorm : Competition w Giants ? running into  resistances . not doing own research caus riding on originals . now playing  catchup - Penicillan - Gard Burn rate ?  | 12 x 300E3 |>| 3600000  =-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-